Dataset Information


Immunological effects of BRAF+MEK inhibition.

ABSTRACT: Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is more evident in patients with favorable baseline characteristics, namely normal levels of lactate dehydrogenase, without brain metastases, and low tumor burden. This long-term benefit of targeted therapies might be related to an immune-modulation: indeed BRAF and MEK inhibitors affect tumor microenvironment and immune surveillance, and it has been shown that patients with complete response to targeted treatment have a pre-existing favorable immunologic signature.


PROVIDER: S-EPMC6140547 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7133746 | BioStudies
2019-01-01 | S-EPMC6853121 | BioStudies
2019-01-01 | S-EPMC6966686 | BioStudies
2015-01-01 | S-EPMC4458462 | BioStudies
2015-01-01 | S-EPMC4765379 | BioStudies
2018-01-01 | S-EPMC6148266 | BioStudies
2017-01-01 | S-EPMC5653517 | BioStudies
1000-01-01 | S-EPMC6201855 | BioStudies
1000-01-01 | S-EPMC6038340 | BioStudies
2016-01-01 | S-EPMC4930524 | BioStudies